+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Economic Evaluation Of A Pharmacogenomic Test For Statin-Induced Myopathy In Cardiovascular High-Risk Patients Initiating A Statin



Economic Evaluation Of A Pharmacogenomic Test For Statin-Induced Myopathy In Cardiovascular High-Risk Patients Initiating A Statin



Value in Health 18(7): A396




(PDF emailed within 0-6 h: $19.90)

Accession: 057685257

Download citation: RISBibTeXText

PMID: 26532235

DOI: 10.1016/j.jval.2015.09.896


Related references

Economic Evaluation of a Pharmacogenomics Test for Statin-Induced Myopathy in Cardiovascular High-Risk Patients Initiating a Statin. Molecular Diagnosis and Therapy 21(1): 95-105, 2016

A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular Prevention. Molecular Diagnosis and Therapy 22(2): 241-254, 2018

Value of a Hypothetical Pharmacogenomic Test for the Diagnosis of Statin-Induced Myopathy in Patients at High Cardiovascular Risk. Molecular Diagnosis and Therapy 2018, 2018

Treatment Patterns, Statin Intolerance, and Subsequent Cardiovascular Events Among Japanese Patients With High Cardiovascular Risk Initiating Statin Therapy. Circulation Journal 82(4): 1008-1016, 2017

Economic Evaluation of the 2016 Chinese Guideline and Alternative Risk Thresholds of Initiating Statin Therapy for the Management of Atherosclerotic Cardiovascular Disease. Pharmacoeconomics 2019, 2019

Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events. American Journal of Cardiology 89(4): 390-394, February 15, 2002

Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991-2006. Plos One 3(6): E2522, 2008

Pharmacogenomic insights into treatment and management of statin-induced myopathy. Genome Medicine 1(12): 120, 2010

Large copy-number variations in patients with statin-associated myopathy affecting statin myopathy-related loci. Physiological Research 65(6): 1005-1011, 2016

Rechallenging Statin Therapy in Veterans With Statin-Induced Myopathy Post Vitamin D Replenishment. Journal of Pharmacy Practice 30(5): 521-527, 2016

Statin-induced necrotizing myositis - a discrete autoimmune entity within the "statin-induced myopathy spectrum". Autoimmunity Reviews 12(12): 1177-1181, 2014

LDL cholesterol response and statin adherence among high-risk patients initiating treatment. American Journal of Managed Care 22(3): E106-E115, 2017

Myopathy induced by statin-ezetimibe combination: Evaluation of potential risk factors. Indian Journal of Pharmacology 47(5): 563-564, 2016

Risk for myopathy with statin therapy in high-risk patients. Archives of Internal Medicine 163(5): 553-564, 2003

Mislabeling of Study Design and Overstatement of Findings in "Rechallenging Statin Therapy in Veterans With Statin-Induced Myopathy Post Vitamin D Replenishment". Journal of Pharmacy Practice 30(3): 385, 2018